Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 82, Issue SUPPL. 1, 2008, Pages

  Nakagawa, Takahiko ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Diabetic nephropathy; Endothelial dysfunction; Nitric oxide; VEGF

Indexed keywords

CYCLOSPORIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; DIABETIC NEPHROPATHY; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55249091081     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.030     Document Type: Article

References (20)

1. Saito Y., Kida H., Takeda S., Yoshimura M., Yokoyama H., Koshino Y., et al. Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int. 34 (1988) 389-396
2. Stout L.C., Kumar S., and Whorton E.B. Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. Hum. Pathol. 24 (1993) 77-89
3. Min W., and Yamanaka N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch. A: Pathol. Anat. Histopathol. 423 (1993) 201-207
4. Breyer M.D., Bottinger E., Brosius III F.C., Coffman T.M., Harris R.C., Heilig C.W., et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 27-45
5. Kanesaki Y., Suzuki D., Uehara G., Toyoda M., Katoh T., Sakai H., et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45 (2005) 288-294
6. Kang D., Nakagawa T., Feng L., and Johnson R.J. Nitric oxide modulates vascular disease in the remnant kidney model. Am. J. Pathol. 161 (2002) 239-248
7. Kang D.H., Kim Y.G., Andoh T.F., Gordon K.L., Suga S., Mazzali M., et al. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am. J. Physiol.: Renal Physiol. 280 (2001) F727-F736
8. Masuda Y., Shimizu A., Mori T., Ishiwata T., Kitamura H., Ohashi R., et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am. J. Pathol. 159 (2001) 599-608
9. de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., and Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12 (2001) 993-1000
10. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G., and Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51 (2002) 3090-3094
11. Flyvbjerg A., Schrijvers B.F., De Vriese A.S., Tilton R.G., and Rasch R. Compensatory glomerular growth after unilateral nephrectomy is VEGF dependent. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E362-366
12. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634
13. Brodsky S.V., Gao S., Li H., and Goligorsky M.S. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H2130-H2139
14. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., and Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108 (2001) 1341-1348
15. Da Silva-Azevedo L., Baum O., Zakrzewicz A., and Pries A.R. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem. Biophys. Res. Commun. 297 (2002) 1270-1276
16. Bussolati B., Dunk C., Grohman M., Kontos C.D., Mason J., and Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor mediated angiogenesis via nitric oxide. Am. J. Pathol. 159 (2001) 993-1008
17. Zhao Q., Egashira K., Inoue S., Usui M., Kitamoto S., Ni W., et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105 (2002) 1110-1115
18. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am. J. Physiol.: Renal Physiol. 292 (2007) F1665-F1672
19. Galkina E., and Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 17 (2006) 368-377
20. Sato W., Zhang L., Roncal C., Heinig M., Campbell-Thompson M., Atkinson M., et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest. 88 (2008) 946-961